Enanta Pharmaceuticals Inc (ENTA)

[willyw]

100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks

http://www.natap.org/2015/AASLD/AASLD_21.htm

Per the link;
Geno 1 is a 46% prevalence world wide

This was in the higher optimized dosing;
300mg ABT-493 & 120 MG ABT-530

This is just a small trial, but others will be rolling in to confirm results.
Also please note, there is not a lot of difference between 12 and 8 weeks of treatment; close to statistically insignificant.

IMHO, the differences will show themselves in various treatment subtypes